Jupiter Neurosciences, Inc.
JUNSRating Trend
Earnings History
Next report: Dec 2, 2026 · EPS est. $-3.75| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-5.06 | $-3.75 | $24.2K | $400.0K |
| May 21, 2026 | $-4.39 | $-3.75 | $18.7K | $225.0K |
| Apr 3, 2026 | $-5.61 | $-5.25 | $21.8K | $75.0K |
| Dec 22, 2025 | $-5.25 | $-6.00 | — | $75.0K |
| Aug 18, 2025 | $-5.26 | $-5.26 | — | $2.5M |
| May 15, 2025 | $-3.76 | $-2.26 | — | — |
| Mar 28, 2025 | $-3.76 | $-1.50 | — | — |
| Dec 23, 2024 | $-1.50 | — | — | — |
News
First Patient Dosed with JOTROL ™ Marks Major Clinical Milestone for Jupiter Neurosciences' Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL ™ in Patients with Parkinson's Disease
Jupiter Neurosciences announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2M. D. Boral Capital LLC is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about August 24, 2026, subject to the satisfaction of customary closing conditions.
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.
Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) are surging Friday morning as related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S. patent.